Are APMD insiders buying or selling?

In the last 90 days, Apnimed (APMD) had 0 insider transactions. Track every executive trade, dollar amount, and date.

Which hedge funds own APMD?

See every hedge fund and asset manager holding Apnimed (APMD).

How much of APMD trades in dark pools?

0.672M APMD shares ($18M notional) traded off-exchange last week — block trades typical of institutional flow.

Apnimed (APMD) Stock — 61.0% Short — Squeeze Watch

$19.49

+0.54 (+2.85%)

After Hours: $19.62 (+0.13, +0.64%)

Weekly Expected Move ±13.5%

$14 $16 $19 $22 $24

NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 36 · $788.9M mcap · 3M float · 14.71% daily turnover · Short 62% of daily vol

Credit Risk of going bust: not rated Bonds: none of note held by US funds details ▾

Not rated: no recent balance sheet.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Smart Money Score

Watch 25

Insider—

Congress—

ETF Holdings—

Key Statistics

Market Cap$788.9M

52W Range16-35.29

Volume178,483

Avg Volume495,186

Beta0.00

Dividend—

Analyst Ratings

No analyst coverage

Company Info

CEOKevin R. Lind

Employees81

SectorHealthcare

IndustryBiotechnology

IPO Date2026-07-29

Websiteapnimed.com

39 John F. Kennedy Street
Cambridge, MA 02138
US

About Apnimed, Inc.

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Latest News